Summary of the Dasatinib and Quercetin Clinical Trial for Alzheimer’s Disease
The clinical trial investigating the combination of dasatinib and quercetin for Alzheimer’s disease is a pioneering study exploring the potential of senolytic therapy to target cellular senescence, which is believed to contribute to the progression of neurodegenerative diseases like Alzheimer’s.
Study Overview:
- Objective: To evaluate the safety and efficacy of dasatinib (a cancer drug) combined with quercetin (an antioxidant) in treating mild Alzheimer’s disease.
- Type: Phase 1 proof-of-concept trial.
- Participants: Patients with mild Alzheimer’s disease.
Mechanism of Action:
- Dasatinib: A tyrosine kinase inhibitor commonly used to treat leukemia. It works by inducing apoptosis (cell death) in senescent cells.
- Quercetin: A plant flavonoid with antioxidant properties. It complements dasatinib by targeting senescent cells and reducing inflammation.
Rationale:
- Cellular Senescence: Senescent cells accumulate with age and secrete harmful factors that contribute to tissue dysfunction and inflammation. Removing these cells can potentially mitigate these adverse effects.
- Alzheimer’s Disease: Senescent cells in the brain may exacerbate the pathology of Alzheimer’s by promoting inflammation and neuronal damage.
Preliminary Results:
- Safety Profile: The combination therapy showed a good safety profile, with no significant adverse effects reported in the preliminary phase.
- Efficacy Indicators: There were promising trends in reducing biomarkers related to inflammation and amyloid plaques, which are hallmarks of Alzheimer’s disease.
Implications:
- Innovative Approach: This trial is among the first to apply senolytic therapy to Alzheimer’s, marking a novel therapeutic strategy that targets the underlying biological mechanisms of aging.
- Future Potential: If further trials confirm these results, dasatinib and quercetin could become part of a new class of treatments aimed at slowing down or reversing the progression of Alzheimer’s by addressing cellular senescence.
Next Steps:
- Extended Trials: Further phases involving larger participant groups and longer follow-up periods are necessary to validate these findings and establish long-term efficacy and safety.
- Comprehensive Studies: Additional research into the mechanisms by which senolytic therapy affects Alzheimer’s progression will help refine and optimize treatment protocols.
https://www.medpagetoday.com/neurology/alzheimersdisease/108094
Novel Alzheimer’s Trials Evaluate Senolytics, Semaglutide, CRISPR, and More